Abstract:With the application of Mendelian randomization and co‐localization analysis methods, we found compelling indications for two proteins (LRP11 and ITIH1) and suggested indications for four proteins (PLCG1, ARHGAP25, CHGA, and MANBA), which might be promising targets for migraine treatment without obvious adverse consequences. Background Proteome‐wide Mendelian randomization studies have been increasingly utilized to identify potential drug targets for diseases. We aimed to identify potential therapeutic targets for migraine and its subtypes through the application of Mendelian randomization and co‐localization analysis methods. Methods We utilized cis‐protein quantitative trait loci data for 1378 plasma proteins available from two studies with 7213 individuals and 35,559 individuals, respectively. Summary data for migraine and its subtypes were obtained from a genetic study involving up to 1,339,303 individuals. Proteins that passed both the discovery and validation Mendelian randomization analysis, sensitivity analysis, heterogeneity test, and pleiotropy test, were associated with ≥2 outcomes, and received strong support from co‐localization analysis (PP.H4.abf ≥0.80) and were classified as tier 1 proteins. Results We identified three tier 1 proteins (LRP11, ITIH1, and ADGRF5), whose genes have not been previously identified as causal genes for migraine in genetic studies. LRP11 was significantly associated with the risk of any migraine (OR [odds ratio] = 0.968, 95% CI [confidence interval] = 0.955–0.981, p = 1.27 × 10−6) and significantly/suggestively associated with three migraine subtypes. ITIH1 was significantly associated with the risk of any migraine (OR = 1.044, 95% CI = 1.024–1.065, p = 1.08 × 10−5) and migraine with visual disturbances. ADGRF5 was significantly associated with the risk of any migraine (OR = 0.964, 95% CI = 0.946–0.982, p = 8.74 × 10−5) and suggestively associated with migraine with aura. The effects of LRP11 and ADGRF5 were further replicated using cerebrospinal fluid protein data. Apart from ADGRF5, there was no evidence of potential adverse consequences when modulating the plasma levels. We also identified another four proteins (PLCG1, ARHGAP25, CHGA, and MANBA) with no potential adverse consequences when modulating the plasma levels, and their genes were not reported by previous genetic studies. Conclusions We found compelling evidence for two proteins and suggestive evidence for four proteins that could be promising targets for migraine treatment without significant adverse consequences. The corresponding genes were not reported in previous genetic studies. Future studies are needed to confirm the causal role of these proteins and explore the underlying mechanisms.

Non-coding variants in VAMP2 and SNAP25 affect gene expression: potential implications in migraine susceptibility

Integrating functional scoring and regulatory data to predict the effect of non-coding SNPs in a complex neurological disease

Neurobiology of Disease Subunit Susceptibility Variants E 177 A and R 220 H Associated with Complex Epilepsy Alter Channel Gating and Surface Expression of 4 2 GABAA Receptors

Identification of Polymorphisms in EAAT1 Glutamate Transporter Gene SLC1A3 Associated with Reduced Migraine Risk

A splice variant in the ACSL5 gene relates migraine with fatty acid activation in mitochondria

Genetics of migraine: complexity, implications, and potential clinical applications

Comprehensive analysis of genetic associations and single-cell expression profiles reveals potential links between migraine and multiple diseases: a phenome-wide association study

Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles

IL18 rs360717 and rs187238 genetic variants are associated with migraine diagnosis

MTHFR polymorphism's influence on the clinical features and therapeutic effects in patients with migraine: An observational study.

Meta-analysis of 375,000 Individuals Identifies 38 Susceptibility Loci for Migraine

A cross-tissue transcriptome-wide association study reveals novel susceptibility genes for migraine

Gene co-expression analysis identifies brain regions and cell types involved in migraine pathophysiology: a GWAS-based study using the Allen Human Brain Atlas

Association between MAPK and PI3K/Akt signaling pathway-related gene polymorphisms and migraine

The impact of genetic factors on the response to migraine therapy

A new gene for autosomal dominant facial palsy/migraine identified in a family by whole exome sequencing

Effect of disease‐associated variants in TREM2 on splicing and gene dosage

Association between TRP channels and glutamatergic synapse gene polymorphisms and migraine and the comorbidities anxiety and depression in a Chinese population

Identifying novel proteins for migraine by integrating proteomes from blood and CSF with genome‐wide association data

Genetic mechanisms underlying local spontaneous brain activity in episodic migraine

Multiomic‐based immune response profiling in migraine, vestibular migraine and Meniere's disease